A new White House initiative to address rising U.S. heroin use will increase funds to pinpoint the sources of heroin as well as hot spots for drug overdoses. Baker Institute Blog: http://bit.ly/1h0W7r2
In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?
Elaine Howard Ecklund, Kirstin R.W. MatthewsJune 1, 2015
Drug policy has experienced an interesting shift recently. Along with legalization of medical and recreational marijuana, many states are also reducing penalties for nonviolent drug offenses and placing greater focus on treatment for drug users. The emphasis on treatment and rehabilitation for drug users is the result of many factors, including recognition that the drug war has not reduced drug use, a desire to reduce the prison population and save money, and a surge in the rate of overdoses from opioid and heroin use. What remains to be seen is whether the current popularity of drug treatment will become a more permanent feature of drug policy. In this Baker Institute Viewpoints series, five experts on drug policy examine the question, “Is the current emphasis on treatment in drug policy a short-term trend or is it here to stay?”
Katharine Neill Harris, William MartinDecember 19, 2014
In this Baker Institute Viewpoints series, five experts on the marijuana industry examine the question, “What does the future hold for the cannabis industry, in Texas and beyond?”
In the current campaign for Harris County district attorney, both incumbent D.A. Devon Anderson and challenger Kim Ogg have not only proposed to change the way marijuana use is handled by that office, but have also made the issue a centerpiece of their campaigns. Drug policy fellow Katharine Neill examines each candidate’s proposed changes in a new Baker Institute Blog.
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
Baker Institute health policy experts Hagop M. Kantarjian and Vivian Ho explain why Texas, which holds the notorious record of the highest rate of uninsured citizens in the U.S., should follow many Republican-led states that are now reconsidering the Medicaid expansion program under Obamacare.